论文部分内容阅读
处方药品价格虚高是美国目前亟待解决的问题。联邦政府试图采取多种措施进行改革,如进行直接议价、取消具有欺骗行为的药品公司的市场独家经销权等。但这些措施会减少患者对新药品的可及性以及制药公司的创新积极性,此外,制药公司通过《可负担的医疗法案》(the Affordable Care Act)以提供经济支持,规避政府直接议价。2016年2月,《The New England Journal of Medicine》杂志发表了题为“Pharmaceutical Policy Reform—Balancing Affordability with Incentives for Inno-
The high price of prescription drugs is a problem that the United States urgently needs to solve now. The federal government is trying to take various measures to reform, such as direct bargaining, the elimination of the market exclusive distribution rights of drug companies with fraud and so on. But these measures will reduce patient access to new medicines and the innovative enthusiasm of pharmaceutical companies. In addition, pharmaceutical companies use the Affordable Care Act to provide financial support to circumvent government direct bargaining. In February 2016, The New England Journal of Medicine published a paper entitled ”Pharmaceutical Policy Reform-Balancing Affordability with Incentives for Inno-